Found: 33
Select item for more details and to access through your institution.
A phase II trial of apalutamide for intermediate‐risk prostate cancer and molecular correlates.
- Published in:
- BJU International, 2024, v. 134, n. 3, p. 449, doi. 10.1111/bju.16414
- By:
- Publication type:
- Article
Efficacy, Safety, and Tolerability of Tivozanib in Heavily Pretreated Patients With Advanced Clear Cell Renal Cell Carcinoma.
- Published in:
- Oncologist, 2024, v. 29, n. 7, p. 589, doi. 10.1093/oncolo/oyae037
- By:
- Publication type:
- Article
Treatment Outcomes in Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid and/or Rhabdoid Dedifferentiation After Progression on Immune Checkpoint Therapy.
- Published in:
- Oncologist, 2024, v. 29, n. 5, p. 392, doi. 10.1093/oncolo/oyad302
- By:
- Publication type:
- Article
Differential Treatment Effects of Subgroup Analyses in Phase 3 Oncology Trials From 2004 to 2020.
- Published in:
- JAMA Network Open, 2024, v. 7, n. 3, p. e243379, doi. 10.1001/jamanetworkopen.2024.3379
- By:
- Publication type:
- Article
Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2023, v. 115, n. 12, p. 1605, doi. 10.1093/jnci/djad155
- By:
- Publication type:
- Article
The Influence of Obesity on Outcomes with Immune Checkpoint Blockade: Clinical Evidence and Potential Biological Mechanisms.
- Published in:
- Cells (2073-4409), 2023, v. 12, n. 21, p. 2551, doi. 10.3390/cells12212551
- By:
- Publication type:
- Article
Cardiometabolic healthcare for men with prostate cancer: an MD Anderson Cancer Center experience.
- Published in:
- Cardio-Oncology, 2023, v. 9, n. 1, p. 1, doi. 10.1186/s40959-023-00186-x
- By:
- Publication type:
- Article
Cancer Cell–Extrinsic Roles for the Androgen Receptor in Prostate Cancer.
- Published in:
- Endocrinology, 2023, v. 164, n. 6, p. 1, doi. 10.1210/endocr/bqad078
- By:
- Publication type:
- Article
Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell Carcinomas.
- Published in:
- Oncologist, 2023, v. 28, n. 5, p. 433, doi. 10.1093/oncolo/oyac262
- By:
- Publication type:
- Article
Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies.
- Published in:
- NPJ Precision Oncology, 2023, v. 7, n. 1, p. 1, doi. 10.1038/s41698-023-00369-w
- By:
- Publication type:
- Article
Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas.
- Published in:
- Oncologist, 2022, v. 27, n. 12, p. 1041, doi. 10.1093/oncolo/oyac158
- By:
- Publication type:
- Article
Missing the trees for the forest: most subgroup analyses using forest plots at the ASCO annual meeting are inconclusive.
- Published in:
- Therapeutic Advances in Medical Oncology, 2022, p. 1, doi. 10.1177/17588359221103199
- By:
- Publication type:
- Article
First-Line Immuno-Oncology Combinations for Metastatic Clear Cell Renal Cell Carcinoma (mRCC): A Systematic Review of Phase III Clinical Trials.
- Published in:
- Kidney Cancer (2468-4562), 2021, v. 5, n. 4, p. 207, doi. 10.3233/KCA-210123
- By:
- Publication type:
- Article
Radium-223 plus Enzalutamide Versus Enzalutamide in Metastatic Castration-Refractory Prostate Cancer: Final Safety and Efficacy Results.
- Published in:
- Oncologist, 2021, v. 26, n. 12, p. 1006, doi. 10.1002/onco.13949
- By:
- Publication type:
- Article
Pembrolizumab for advanced penile cancer: a case series from a phase II basket trial.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 5, p. 1405, doi. 10.1007/s10637-021-01100-x
- By:
- Publication type:
- Article
Identification of Somatic Gene Signatures in Circulating Cell‐Free DNA Associated with Disease Progression in Metastatic Prostate Cancer by a Novel Machine Learning Platform.
- Published in:
- Oncologist, 2021, v. 26, n. 9, p. 751, doi. 10.1002/onco.13869
- By:
- Publication type:
- Article
Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor‐Tyrosine Kinase Inhibitor Therapies.
- Published in:
- Oncologist, 2021, v. 26, n. 6, p. 476, doi. 10.1002/onco.13770
- By:
- Publication type:
- Article
Successful Recruitment of Black Men to Prostate Cancer Clinical Trials—A Lesson in Achievement.
- Published in:
- 2021
- By:
- Publication type:
- Opinion
Potential Roles for PD‐1 Inhibition and Cabozantinib in Patients with Metastatic Non‐Clear Cell Renal Cell Carcinoma.
- Published in:
- Oncologist, 2020, v. 25, n. 3, p. 186, doi. 10.1634/theoncologist.2019-0657
- By:
- Publication type:
- Article
A Phase I Study of Alpha‐1,3‐Galactosyltransferase‐Expressing Allogeneic Renal Cell Carcinoma Immunotherapy in Patients with Refractory Metastatic Renal Cell Carcinoma.
- Published in:
- Oncologist, 2020, v. 25, n. 2, p. 121, doi. 10.1634/theoncologist.2019-0599
- By:
- Publication type:
- Article
Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Treatment Decisions for Metastatic Clear Cell Renal Cell Carcinoma in Older Patients: The Role of TKIs and Immune Checkpoint Inhibitors.
- Published in:
- Drugs & Aging, 2019, v. 36, n. 5, p. 395, doi. 10.1007/s40266-019-00644-1
- By:
- Publication type:
- Article
Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future Direction.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Targeting Endoglin to Treat Metastatic Renal Cell Carcinoma: Lessons from Osler‐Weber‐Rendu Syndrome.
- Published in:
- Oncologist, 2019, v. 24, n. 2, p. 143, doi. 10.1634/theoncologist.2018-0443
- By:
- Publication type:
- Article
Predictive genomic markers of response to VEGF targeted therapy in metastatic renal cell carcinoma.
- Published in:
- PLoS ONE, 2019, v. 14, n. 1, p. 1, doi. 10.1371/journal.pone.0210415
- By:
- Publication type:
- Article
Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA.
- Published in:
- 2018
- By:
- Publication type:
- journal article
The Role of Circulating Tumor DNA in Renal Cell Carcinoma.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma.
- Published in:
- 2018
- By:
- Publication type:
- journal article
9p24 abnormalities in hematologic malignancies with a focus on diffuse large B-cell lymphoma.
- Published in:
- 2017
- By:
- Publication type:
- letter
Neutrophil-lymphocyte ratio as a predictive biomarker for response to high dose interleukin-2 in patients with renal cell carcinoma.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Complete response to azacitidine priming and nab-paclitaxel in non-Hodgkin lymphoma resistant to biochemotherapy.
- Published in:
- Molecular & Clinical Oncology, 2017, v. 6, n. 1, p. 122, doi. 10.3892/mco.2016.1090
- By:
- Publication type:
- Article
Conditional survival of metastatic renal cell carcinoma patients treated with high-dose interleukin-2.
- Published in:
- Ecancermedicalscience, 2016, v. 10, n. 674-708, p. 1, doi. 10.3332/ecancer.2016.676
- By:
- Publication type:
- Article
How Center Volumes Affect Early Outcomes in Acute Myeloid Leukemia.
- Published in:
- 2015
- By:
- Publication type:
- journal article